Literature DB >> 15593390

Surgical management of gastric stump cancer: a report of 37 cases.

Li Chen1, Hua Tian, Jian Chen, Zhi-gang He, Si-feng Tao, Gurung Lokesh, Shu-you Peng.   

Abstract

OBJECTIVE: To observe the clinicopathological characteristics of gastric stump cancer (GSC) and evaluate the benefits of radical surgery of GSC.
METHODS: The clinicopathological characteristics and postoperative survival time of 37 GSC patients who underwent surgery were investigated retrospectively. The survival time was compared according to the type of surgical operation (radical resection vs palliative operation). Twenty-one cases that received radical resection were analyzed based on the pTMN stage. Survival curves were traced by using Kaplan-Meier methods.
RESULTS: Most GSC (32/37) was detected in patients who had received Billroth II reconstruction after partial gastrectomy for benign gastric disease. The lesser curvature side and the suture line of anastomosis were the most frequent sites where GSC occurred (27/37). Differentiated adenocarcinoma was the dominant histopathological type (24/37). The postoperative 5-year survival rate of early stage GSC patients (n=9) was significantly higher than advanced stage GSC (n=12) (55.6% vs 16.5%, xL2=11.48, P<0.01). Five-year survival rate of 21 GSC patients with radical resection were 75% (3/4) for stage I, 60% (3/5) for stage II, 14.2% (1/7) for stage III, and 0% (0/5) for stage IV respectively. The median survival time of 21 GSC patients who underwent radical resection was longer than those undergoing palliative operation (43.0 m vs 13.0 m, x L2=36.31, P<0.01), the median survival time of stage IV patients with radical resection was 23.8 months.
CONCLUSIONS: Without remote metastasis, radical resection for GSC is possible, and is an effective way to improve the prognosis of GSC. Even in stage IV GSC, radical resection can still prolong the survival time. It is necessary for the patients with benign gastric diseases who received partial gastrectomy to carry out the endoscopy follow-up, especially in patients with Billroth II reconstruction procedure at 15-20 years.

Entities:  

Mesh:

Year:  2005        PMID: 15593390      PMCID: PMC1390757          DOI: 10.1631/jzus.2005.B0038

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  13 in total

1.  Quantitative determinations of duodenogastric reflux, prevalence of Helicobacter pylori infection, and concentrations of interleukin-8.

Authors:  Kenichiro Fukuhara; Harushi Osugi; Nobuyasu Takada; Masashi Takemura; Yasukazu Ohmoto; Hiroaki Kinoshita
Journal:  World J Surg       Date:  2003-04-28       Impact factor: 3.352

2.  Early gastric stump cancer following distal gastrectomy.

Authors:  K Kaneko; H Kondo; D Saito; K Shirao; H Yamaguchi; T Yokota; G Yamao; T Sano; M Sasako; S Yoshida
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

3.  Early cancer of the gastric remnant.

Authors:  R Pointner; G Schwab; A Königsrainer; E Bodner; K W Schmid
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

4.  Is gastric remnant cancer clinically different from primary gastric cancer?

Authors:  S S Lo; C W Wu; M C Hsieh; W Y Lui
Journal:  Hepatogastroenterology       Date:  1997 Jan-Feb

5.  Lymph node dissection in surgical treatment for remnant stomach cancer.

Authors:  Chikara Kunisaki; Hiroshi Shimada; Masato Nomura; Noriomi Hosaka; Hirotoshi Akiyama; Kenji Ookubo; Yoshihiro Moriwaki; Hiroyuki Yamaoka
Journal:  Hepatogastroenterology       Date:  2002 Mar-Apr

6.  Different characteristics of carcinoma in the gastric remnant: histochemical and immunohistochemical studies.

Authors:  N Matsui; T Yao; K Akazawa; H Nawata; M Tsuneyoshi
Journal:  Oncol Rep       Date:  2001 Jan-Feb       Impact factor: 3.906

7.  Japanese Classification of Gastric Carcinoma - 2nd English Edition -

Authors: 
Journal:  Gastric Cancer       Date:  1998-12       Impact factor: 7.370

8.  Gastric remnant carcinoma: reevaluation of screening endoscopy.

Authors:  C J Gannon; B Engbrecht; L M Napolitano; B L Bass
Journal:  Surg Endosc       Date:  2001-12       Impact factor: 4.584

9.  Clinical study to identify specific characteristics of cancer newly developed in the remnant stomach.

Authors:  Nobuhiko Tanigawa; Eiji Nomura; Masami Niki; Hisashi Shinohara; Kanji Nishiguchi; Masaaki Okuzawa; Masao Toyoda; Shinsho Morita
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

10.  Management of gastric remnant carcinoma based on the results of a 15-year endoscopic screening program.

Authors:  F L Greene
Journal:  Ann Surg       Date:  1996-06       Impact factor: 12.969

View more
  7 in total

1.  Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.

Authors:  Jing-Ting Jiang; Yue-Ping Shen; Chang-Ping Wu; Yi-Bei Zhu; Wen-Xiang Wei; Lu-Jun Chen; Xiao Zheng; Jing Sun; Bin-Feng Lu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

2.  Clinicopathologic features of remnant gastric cancer over time following distal gastrectomy.

Authors:  De-Wei Zhang; Biao Dong; Zhen Li; Dong-Qiu Dai
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

3.  Gastric Adenocarcinoma in the Duodenal Stump 40 Years After a Billroth II Partial Gastrectomy for Benign Indications.

Authors:  Jessica F Rose; Lenka Stankova; Evan S Glazer; Hugo V Villar
Journal:  Gastrointest Cancer Res       Date:  2012-07

4.  Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer.

Authors:  X Wang; M L Wang; L Y Zhou; X Y Lu; J F Yang; H G Yu
Journal:  Clin Transl Oncol       Date:  2013-02-05       Impact factor: 3.405

5.  Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer.

Authors:  Xiao-Dong Li; Hua Shen; Jing-Ting Jiang; Han-Ze Zhang; Xiao Zheng; Yong-Qian Shu; Chang-Ping Wu
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

6.  Clinical significance of tumor location in remnant gastric cancers developed after partial gastrectomy for primary gastric cancer.

Authors:  Ji Yeong An; Ho Geun Youn; Tae Kyung Ha; Min Gew Choi; Kyoung-Mee Kim; Jae Hyung Noh; Tae Sung Sohn; Sung Kim
Journal:  J Gastrointest Surg       Date:  2007-12-13       Impact factor: 3.452

7.  Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.

Authors:  Xichao Dai; Xizhi Zhang; Chaomin Wang; Jingting Jiang; Changping Wu
Journal:  Oncotarget       Date:  2017-05-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.